Advertisement


Robert J. Motzer, MD, on RCC: Quality of Life for Patients Treated With Lenvatinib-Based Therapy vs Sunitinib

2021 ASCO Annual Meeting

Advertisement

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses health-related quality-of-life data from the phase III CLEAR trial, which compared lenvatinib plus pembrolizumab or everolimus vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (Abstract 4502).



Related Videos

Breast Cancer
Immunotherapy

Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab

Sibylle Loibl, MD, PhD, of the German Breast Group, discusses results from the phase III GeparNUEVO study, which investigated neoadjuvant durvalumab in addition to anthracycline/taxane-based neoadjuvant chemotherapy in patients with early triple-negative breast cancer (Abstract 506).

Prostate Cancer
Issues in Oncology

Peter C. Black, MD, on Prostate Cancer Health-Care Disparities: Expert Perspective

Peter C. Black, MD, of the Vancouver Prostate Centre, University of British Columbia, reviews three studies on early detection and treatment of Black patients with prostate cancer: a large-scale analysis of genomic profiling; the use of PSA screening; and integrating a patient-specific genomic classifier to improve risk classification and treatment recommendations for Black men (Abstracts 5003, 5004, and 5005).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Pembrolizumab vs Placebo in Adjuvant Treatment

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results from KEYNOTE-564, which evaluated the safety and efficacy of pembrolizumab in the adjuvant treatment of patients with renal cell carcinoma who have undergone nephrectomy for intermediate-high or high-risk disease or no evidence of disease (Abstract LBA5).

Breast Cancer

Nadia Harbeck, MD, PhD, on Luminal Breast Cancer: Prognostic Impact of Recurrence Score, Endocrine Response, and Other Factors

Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses first phase III results from a prospective high-risk cohort of patients with luminal breast cancer, which showed a good prognosis in some women with more than four positive lymph nodes and low recurrence scores. The study also showed that a lower postendocrine Ki67 index and limited tumor burden may be promising criteria for chemotherapy de-escalation strategies, even in patients with high recurrence scores (Abstract 504).

Lung Cancer
Genomics/Genetics
Immunotherapy

Pasi A. Janne, MD, PhD, on NSCLC: Patritumab Deruxtecan to Target HER3

Pasi A. Janne, MD, PhD, of Dana-Farber Cancer Institute, discusses study findings that show patritumab deruxtecan is effective in patients with EGFR-mutated and inhibitor-resistant non–small cell lung cancer. Dr. Janne also explains why targeting HER3, a mutation expressed in most EGFR-altered cancers, is a beneficial treatment approach (Abstract 9007).

Advertisement

Advertisement




Advertisement